Related Experiment Video
Updated: Jan 10, 2026
06:55
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
15.0K
The Role Of Drug Indication On Incidence Rate Heterogeneity: A Large-Scale, Systematic Evaluation Across An
Hsin Yi Chen1, Christopher Knoll2, Elise Boventer3
1Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.
Medrxiv : the Preprint Server for Health Sciences
|November 24, 2025
Summary
Drug indication significantly impacts incidence rate estimates, varying by drug class. Age, data source, and indication are key factors influencing these variations, crucial for patient safety evaluations.
Area of Science:
- Pharmacovigilance
- Observational Epidemiology
- Health Outcomes Research
Background:
- Incidence rate estimates are critical for patient safety evaluations.
- Estimates can be influenced by patient demographics (age, sex) and data sources.
- The impact of drug indication on incidence rates is not well understood.
Purpose of the Study:
- To quantify the impact of drug indication on incidence rate estimates.
- To compare the variability of incidence rates across different drug classes and indications.
- To identify factors contributing to incidence rate heterogeneity.
Main Methods:
- An observational cohort study using 13 healthcare databases.
- Estimated incidence rates for 73 health outcomes across 8 drug classes.
- Utilized variance components analysis to assess variability from database, age, sex, and indication.
Main Results:
- Substantial variation in incidence rates across indications was observed for some drug classes.
- Age was often the strongest contributor to incidence variation within drug classes.
- Trimethoprim, SGLT-2 inhibitors, and beta blockers showed higher variability (VC) compared to GLP-1 agonists.
Conclusions:
- Drug indication is an important, often underexplored, factor in incidence rate estimation.
- Accounting for drug indication is essential for accurate patient safety assessments.
- Findings highlight the need to consider indication when interpreting observational study results.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
143
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
143
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
387
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387
01:12Hazard Ratio
551
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
551
01:12Analysis of Population Pharmacokinetic Data
659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
01:29Bias in Epidemiological Studies
1.2K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.2K
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K